PE20220345A1 - Derivados de alcohol como abridores del canal de potasio kv7 - Google Patents

Derivados de alcohol como abridores del canal de potasio kv7

Info

Publication number
PE20220345A1
PE20220345A1 PE2022000184A PE2022000184A PE20220345A1 PE 20220345 A1 PE20220345 A1 PE 20220345A1 PE 2022000184 A PE2022000184 A PE 2022000184A PE 2022000184 A PE2022000184 A PE 2022000184A PE 20220345 A1 PE20220345 A1 PE 20220345A1
Authority
PE
Peru
Prior art keywords
alkyl
cycloalkyl
dimethylpentanamide
trifluoromethoxy
hydroxy
Prior art date
Application number
PE2022000184A
Other languages
English (en)
Spanish (es)
Inventor
Anette Graven Sams
Mario Rottlander
Krestian Larsen
Xiaofang Wang
Debasis Das
Jian Hong
Shu Hui Chen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PE20220345A1 publication Critical patent/PE20220345A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PE2022000184A 2019-08-02 2020-07-30 Derivados de alcohol como abridores del canal de potasio kv7 PE20220345A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19189750 2019-08-02
CN201910734123 2019-08-09
EP19191887 2019-08-15
PCT/EP2020/071520 WO2021023617A1 (en) 2019-08-02 2020-07-30 Alcohol derivatives as kv7 potassium channel openers

Publications (1)

Publication Number Publication Date
PE20220345A1 true PE20220345A1 (es) 2022-03-14

Family

ID=71894829

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000184A PE20220345A1 (es) 2019-08-02 2020-07-30 Derivados de alcohol como abridores del canal de potasio kv7

Country Status (26)

Country Link
EP (2) EP4007634B1 (https=)
JP (2) JP7720829B2 (https=)
CN (1) CN114206830B (https=)
AU (1) AU2020325517B2 (https=)
BR (1) BR112021006324A2 (https=)
CA (1) CA3148719A1 (https=)
CL (1) CL2022000221A1 (https=)
CO (1) CO2022000080A2 (https=)
CR (1) CR20220028A (https=)
DO (1) DOP2022000026A (https=)
EC (1) ECSP22008993A (https=)
ES (1) ES2989376T3 (https=)
GE (2) GEAP202415862A (https=)
HR (1) HRP20241444T1 (https=)
HU (1) HUE069310T2 (https=)
IL (1) IL290193B2 (https=)
JO (1) JOP20220017A1 (https=)
MA (1) MA56708B1 (https=)
MX (1) MX2022001063A (https=)
PE (1) PE20220345A1 (https=)
PH (1) PH12022550192A1 (https=)
PL (1) PL4007634T3 (https=)
RS (1) RS66130B1 (https=)
SM (1) SMT202400445T1 (https=)
WO (1) WO2021023617A1 (https=)
ZA (1) ZA202109598B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66130B1 (sr) * 2019-08-02 2024-11-29 H Lundbeck As Derivati alkohola kao otvarači kv7 kalijumovih kanala
IL325387A (en) * 2023-06-27 2026-02-01 Saniona As KV7 modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092526A1 (en) 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
TWI453013B (zh) 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
WO2007104717A1 (en) * 2006-03-15 2007-09-20 Neurosearch A/S Quinazolinones and their use as potassium channels activators
AR070513A1 (es) 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
TW201024286A (en) * 2008-11-27 2010-07-01 Neurosearch As Novel compounds
HK1216095A1 (zh) * 2012-12-10 2016-10-14 H. Lundbeck A/S 烟碱乙酰胆碱受体的新的正向别构调节剂
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
SMT202300362T1 (it) * 2014-09-12 2023-11-13 Biohaven Therapeutics Ltd Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
CN105663136A (zh) * 2016-01-15 2016-06-15 河北中医学院 法舒地尔作为制备选择性Kv7离子通道激活剂药物的应用
EP4241843B1 (en) * 2018-02-20 2025-05-21 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers
RS66130B1 (sr) * 2019-08-02 2024-11-29 H Lundbeck As Derivati alkohola kao otvarači kv7 kalijumovih kanala
CN114206328B (zh) * 2019-08-02 2024-09-17 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物

Also Published As

Publication number Publication date
CA3148719A1 (en) 2021-02-11
JP7720829B2 (ja) 2025-08-08
JP2025160211A (ja) 2025-10-22
RS66130B1 (sr) 2024-11-29
KR20220041084A (ko) 2022-03-31
JOP20220017A1 (ar) 2023-01-30
GEAP202415862A (en) 2024-01-25
ES2989376T3 (es) 2024-11-26
CO2022000080A2 (es) 2022-01-17
SMT202400445T1 (it) 2024-11-15
HRP20241444T1 (hr) 2024-12-20
CR20220028A (es) 2022-03-02
DOP2022000026A (es) 2022-03-31
CN114206830B (zh) 2024-07-30
PH12022550192A1 (en) 2022-11-21
GEP20247629B (en) 2024-06-10
ECSP22008993A (es) 2022-03-31
MA56708B1 (fr) 2024-12-31
IL290193B1 (en) 2024-08-01
IL290193A (en) 2022-03-01
IL290193B2 (en) 2024-12-01
ZA202109598B (en) 2024-04-24
WO2021023617A1 (en) 2021-02-11
EP4007634B1 (en) 2024-10-02
MX2022001063A (es) 2022-02-14
EP4461725A3 (en) 2025-01-15
EP4461725A2 (en) 2024-11-13
PL4007634T3 (pl) 2024-11-25
AU2020325517B2 (en) 2025-08-28
AU2020325517A1 (en) 2022-02-24
HUE069310T2 (hu) 2025-02-28
CN114206830A (zh) 2022-03-18
BR112021006324A2 (pt) 2022-02-15
EP4007634C0 (en) 2024-10-02
JP2022543203A (ja) 2022-10-11
CL2022000221A1 (es) 2022-10-07
EP4007634A1 (en) 2022-06-08

Similar Documents

Publication Publication Date Title
PE20210397A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cancer
CO2019003482A2 (es) Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
AR070513A1 (es) Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
CR20230529A (es) Inhibidores de nlrp3
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
AR086474A1 (es) Compuestos de pirazol pesticidas
DOP2021000211A (es) Inhibidores de dihidroorotato deshidrogenasa
PE20191005A1 (es) 1,2,4-triazolonas 2,4,5-trisustituidas
PE20180030A1 (es) Compuestos biciclicos de sulfonamida cetona
MY177469A (en) Pyrazole compounds or salts thereof, preparation methods therefor, herbicidal compositions and use thereof
AR065015A1 (es) Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
PE20150339A1 (es) Carboxamidas heterociclicas fungicidas
MA31444B1 (fr) Agents de lutte contre les parasites invertebres
PE20061290A1 (es) Derivados de 1-benzil-indol-2-carboxamida
RU2014149183A (ru) Проницаемые ингибиторы гликозидазы и их применения
PE20220345A1 (es) Derivados de alcohol como abridores del canal de potasio kv7
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
CO6260005A2 (es) Composiciones agricolas que comprenden dialquil amidas como solvente
HRP20230808T1 (hr) Derivati alkohola kao otvarači kv7 kalijevih kanala
HRP20050543A2 (en) Substituted indolepyridinium as anti-infective compounds
DOP2022000070A (es) Inhibidor de diacilglicerol aciltransferasa 2
MX2019010169A (es) Compuestos novedosos utiles como abridores del canal de potasio.
PE20181039A1 (es) Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
MX2016008536A (es) Derivados de fluoro-naftilo.
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica